Clarivate
CLVT
1.47
-0.01
-0.34%
Clarivate
US · CLVT
#3290 by market cap
1.47
-0.01
-0.34%
Live - 5344 symbols - heartbeat 195s ago
· 2026-10-08 09:55
Pre-market
1.47
0.00%
After-hours
1.46
-0.68%
- Market cap
- 937.11M
- P/E (TTM)i
- -2.82
- P/Bi
- 0.21
- EPSi
- -0.30
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on CLVT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -0.62, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -3.97% YoY
Margins
- Gross margin
- 66.05%
- Operating margin
- 7.01%
- Net margin
- -8.19%
Key ratios & quality
- Enterprise valuei
- 5.05B
- Altman Z-Scorei
- -0.62
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 968.47M | 974.35M | 1.25B | 1.88B | 2.66B | 2.63B | 2.56B | 2.46B |
| Gross profit | 538.14M | 622.35M | 815.30M | 1.25B | 1.71B | 1.72B | 1.69B | 1.62B |
| Selling & admin expenses | 413.00M | 475.01M | 544.70M | 643.00M | 729.90M | 739.70M | 727.60M | 708.60M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | -111.54M | -48.19M | -28.10M | 62.10M | 266.30M | 274.10M | 234.20M | 172.10M |
| Pretax profit | -236.51M | -248.43M | -353.30M | -258.20M | -3.99B | -1.01B | -553.80M | -193.90M |
| Tax | 5.65M | 10.20M | -2.70M | 12.30M | -28.90M | -101.30M | 82.90M | 7.20M |
| Net profit | -242.16M | -258.63M | -350.60M | -270.50M | -3.96B | -911.20M | -636.70M | -201.10M |
| Basic EPS | -1 | -1 | -1 | 0 | -6 | -1 | -1 | 0 |
| Diluted EPS | -0.79 | -0.94 | -0.82 | -0.61 | -6.24 | -1.47 | -0.96 | -0.30 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 593.70M | 621.40M | 623.10M | 617.00M | 585.50M | 587.30M |
| Gross profit | 386.70M | 417.80M | 404.90M | 412.20M | 393.40M | 401.80M |
| Selling & admin expenses | 178.40M | 181.10M | 170.00M | 179.10M | 176.30M | 181.60M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 24.60M | 48.90M | 40.60M | 58.00M | 29.60M | 36.00M |
| Pretax profit | -85.10M | -59.70M | -24.50M | -24.60M | -28.80M | -260.60M |
| Tax | 18.80M | 12.30M | 3.80M | -27.70M | 11.40M | 8.00M |
| Net profit | -103.90M | -72.00M | -28.30M | 3.10M | -40.20M | -268.60M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.15 | -0.11 | -0.04 | 0.00 | -0.06 | -0.42 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 408.61M | 493.08M | 1.15B | 1.64B | 1.40B | 1.46B | 1.24B | 1.31B |
| Cash & ST investments | 25.58M | 76.13M | 257.73M | 430.90M | 356.80M | 370.70M | 295.20M | 329.20M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 3.71B | 3.79B | 14.79B | 20.18B | 13.94B | 12.71B | 11.49B | 11.07B |
| Total current liabilities | 643.71M | 651.00M | 1.42B | 1.90B | 1.56B | 1.60B | 1.43B | 1.57B |
| Short-term debt | 60.35M | 31.13M | 64.06M | 62.80M | 25.70M | 24.40M | 21.90M | 119.90M |
| Long-term debt | 1.93B | 1.63B | 3.46B | 5.46B | 5.01B | 4.72B | 4.52B | 4.32B |
| Total liabilities | 2,659,067,000.00 | 2,542,772,000.00 | 5,755,908,000.00 | 8,257,100,000.00 | 7,132,400,000.00 | 6,714,500,000.00 | 6,351,200,000.00 | 6,226,500,000.00 |
| Total equity | 1.05B | 1.25B | 9.03B | 11.93B | 6.81B | 5.99B | 5.14B | 4.84B |
| Retained earnings | -632.26M | -890.89M | -1.25B | -1.60B | -5.66B | -6.65B | -7.31B | -7.51B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.35B | 1.34B | 1.29B | 1.31B | 1.30B | 1.21B |
| Cash & ST investments | 354.00M | 352.30M | 318.70M | 329.20M | 232.30M | 217.70M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 11.49B | 11.42B | 11.23B | 11.07B | 10.93B | 10.49B |
| Total current liabilities | 1.54B | 1.48B | 1.49B | 1.57B | 1.54B | 1.44B |
| Short-term debt | 21.00M | 20.10M | 18.70M | 119.90M | 19.10M | 18.30M |
| Long-term debt | 4.52B | 4.52B | 4.42B | 4.32B | 4.28B | 4.21B |
| Total liabilities | 6,465,600,000.00 | 6,427,100,000.00 | 6,323,800,000.00 | 6,226,500,000.00 | 6,138,300,000.00 | 5,948,600,000.00 |
| Total equity | 5.03B | 4.99B | 4.90B | 4.84B | 4.79B | 4.54B |
| Retained earnings | -7.42B | -7.49B | -7.52B | -7.51B | -7.55B | -7.82B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -26.10M | 117.58M | 263.50M | 323.80M | 509.30M | 744.20M | 646.60M | 628.50M |
| Depreciation & amortization | 237.23M | 200.54M | 303.20M | 537.80M | 710.50M | 708.30M | 727.00M | 757.20M |
| Free cash flow | -71.51M | 45.12M | 155.80M | 205.30M | 306.40M | 501.70M | 357.50M | 365.30M |
| Dividends paid | -- | 0 | 0 | -18.90M | -75.40M | -75.50M | -37.70M | 0 |
| Stock buybacks / issuance | 0 | 0 | 843.70M | 708.50M | -175.00M | -100.00M | -200.00M | -224.50M |
| Ending cash balance | 25.58M | 76.14M | 272.40M | 587.60M | 356.80M | 370.70M | 295.20M | 329.20M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 171.20M | 116.30M | 181.10M | 159.90M | 134.70M | 98.70M |
| Depreciation & amortization | 185.40M | 190.90M | 191.80M | 189.10M | 184.00M | 185.70M |
| Free cash flow | 110.30M | 50.30M | 115.50M | 89.20M | 78.90M | 44.00M |
| Dividends paid | -- | -- | -- | 0 | -- | -- |
| Stock buybacks / issuance | -50.00M | -49.50M | -50.00M | -75.00M | -18.10M | 0 |
| Ending cash balance | 354.00M | 362.60M | 318.70M | 329.20M | 242.20M | 217.70M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -20.73 | -17.50 | -1.94 | -3.10 | -50.59 | -19.69 | -13.72 | -4.03 |
| ROA %i | -6.28 | -5.63 | -1.12 | -1.76 | -23.65 | -7.40 | -5.52 | -1.78 |
| ROIC %i | -7.64 | -6.89 | 0.03 | -0.73 | -28.25 | -7.25 | -4.76 | -0.02 |
| 5-year avg ROE %i | -- | -- | -- | -14.75 | -20.77 | -20.56 | -18.80 | -18.24 |
| EBIT margin %i | -4.33 | 1.24 | 0.22 | -0.30 | -139.82 | -27.34 | -10.58 | 2.91 |
| FCF / sales %i | -- | 4.63 | 11.95 | 10.93 | 11.52 | 19.08 | 13.98 | 14.88 |
| Current ratioi | 0.63 | 0.76 | 0.81 | 0.86 | 0.89 | 0.91 | 0.87 | 0.84 |
| Quick ratioi | 0.55 | 0.63 | 0.70 | 0.70 | 0.79 | 0.80 | 0.76 | 0.73 |
| Debt / assetsi | 53.66 | 45.47 | 24.52 | 27.81 | 36.60 | 37.84 | 39.98 | 40.47 |
| LT debt / equityi | 183.72 | 135.58 | 39.43 | 52.69 | 93.69 | 104.01 | 88.96 | 90.02 |
| Interest coveragei | -- | -- | 0.03 | -0.02 | -13.76 | -2.45 | -0.95 | 0.27 |
| Revenue CAGR (3Y) %i | -- | -- | 10.97 | 24.68 | 39.76 | 27.98 | 10.85 | -2.63 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | 89.37 | 47.67 | 20.31 | 6.04 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -14.24 | -8.18 | -7.60 | -4.03 | -2.80 | -7.01 |
| ROA %i | -5.65 | -3.69 | -3.41 | -1.78 | -1.23 | -3.05 |
| ROIC %i | -4.99 | -2.30 | -1.98 | -0.02 | 1.31 | -0.91 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -11.92 | -2.18 | -1.29 | 2.91 | 5.01 | -3.51 |
| FCF / sales %i | 14.08 | 13.84 | 13.40 | 14.88 | 13.65 | 13.58 |
| Current ratioi | 0.88 | 0.91 | 0.87 | 0.84 | 0.84 | 0.85 |
| Quick ratioi | 0.77 | 0.79 | 0.76 | 0.73 | 0.72 | 0.73 |
| Debt / assetsi | 39.98 | 40.16 | 39.90 | 40.47 | 39.67 | 40.60 |
| LT debt / equityi | 90.99 | 91.44 | 90.97 | 90.02 | 90.11 | 93.43 |
| Interest coveragei | -1.09 | -0.20 | -0.12 | 0.27 | 0.47 | -0.33 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Academia and Government is the largest reported line at 51.13% of revenue, across 3 reported segments.
- Intellectual Property follows at 33.76%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Academia and Government51.13%
Intellectual Property33.76%
Life Sciences and Healthcare15.10%
Quote time 2026-10-08 09:55:30 · For reference only, not investment advice and not tailored to your situation.